blockers

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

...arch and development programs includegrowth factor blockers and angiogenesis inhibitors. ImCloneSystems' strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems' headquarters and research operationsare located in ...

New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

...eries of studies comparing two angiotensinreceptor blockers (ARBs) in hypertensive patients with diabeticnephr...ative long term effects of two AT1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: resul...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

...he protective potential of twoangiotensin receptor blockers in hypertensive patients withdiabetic nephropathy....Comparative long term effects of two AT1 receptor blockers onproteinuria in patients with type-2 diabetes andovert nephropathy and hypertension: results of the...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

...alled lymphoma in patients onREMICADE or other TNF blockers are rare but occur more often thanexpected for people in general. People who have been treated forrheumatoid arthritis, Crohn's disease, ankylosing spondylitis, orpsoriatic arthritis for a long time, particularly those with highlyactive disease may b...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

...arch anddevelopment programs include growth factor blockers andangiogenesis inhibitors. ImClone Systems' strategy is to become afully integrated biopharmaceutical company, taking its developmentprograms from the research stage to the market. ImClone Systems'headquarters and research operations are located in ...

Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO

...arch and development programs includegrowth factor blockers and angiogenesis inhibitors. ImCloneSystems' strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems' headquarters and research operationsare located in ...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

...alled lymphoma in patients onREMICADE or other TNF blockers are rare but occur more often thanexpected for people in general. People who have been treated forrheumatoid arthritis, Crohn's disease, ankylosing spondylitis,psoriatic arthritis, or plaque psoriasis for a long time,particularly those with highly ac...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

...ns currently available belong to two classes:alpha blockers (such as FLOMAX(R)[1], CARDURA(R)[2] andHYTRIN(R)[3]) which relax the muscles in the neck of the bladderand in the prostate, but have no direct effect on the prostategrowth itself, and alpha reductase inhibitors (such asPROSCAR(R)[4] and AVODART(R)[5...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

...arch anddevelopment programs include growth factor blockers andangiogenesis inhibitors. ImClone Systems' strategy is to become afully integrated biopharmaceutical company, taking its developmentprograms from the research stage to the market. ImClone Systems'headquarters and research operations are located in ...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

...uppressing the body'simmune response to cancer. PS blockers may have the potential tohelp reverse this suppression and enable the immune system toattack the cancer more effectively. As an anti-cancerimmunotherapeutic, bavituximab may have broad potential in a widevariety of solid cancers. It is currently in P...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

...arch and development programs includegrowth factor blockers and angiogenesis inhibitors. ImCloneSystems' strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems' headquarters and research operationsare located in ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

...arch and development programs includegrowth factor blockers and angiogenesis inhibitors. ImCloneSystems' strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems' headquarters and research operationsare located in ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...arch and development programs includegrowth factor blockers and angiogenesis inhibitors. ImCloneSystems' strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems' headquarters and research operationsare located in ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...arch and development programs includegrowth factor blockers and angiogenesis inhibitors. ImCloneSystems' strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems' headquarters and research operationsare located in ...